checkAd
    Startseite > Aktien > Elicio Therapeutics > Nachrichten
    Elicio Therapeutics Aktie
    9,6500
     
    USD
    +2,55 %
    +0,2400 USD
    Letzter Kurs 02:00:00 Nasdaq
    9,5100
     
    USD
    200 STK
    Geldkurs 13.05.24
    9,6500
     
    USD
    1.100 STK
    Briefkurs 13.05.24
    ISIN: US28657F1030 · WKN: A3CY4J · SYM: ELTX · USA

    Neueste Nachrichten

    Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
    25.04.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
    05.04.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
    29.03.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Announces $6.0 Million Private Placement Financing
    18.03.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
    06.03.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    05.02.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
    25.01.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
    17.01.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
    16.01.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
    11.01.24 · globenewswire · Elicio Therapeutics
    Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
    09.01.24 · globenewswire · Elicio Therapeutics
    Elicio Therapeutics Announces $7.0 Million Private Placement Financing
    22.12.23 · globenewswire · Elicio Therapeutics